INHIBITOR of Vascular endothelial growth factor A inhibitor
Product Description
Vanucizumab (anti-ANG2 & VEGFA) is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab (anti-ANG2 & VEGFA) has antiangiogenic and anticancer effects. Purity ≥90% (SDS-PAGE&SEC) Endotoxin Level ≤1.0EU/mg
Product Properties
Isotype
Human IgG1
Light Chain Type
kappa
SDS-PAGE
146.89 kDa
Purification Method
Protein A purified
Concentration
See COA
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
1448221-05-3
Images
Vanucizumab (anti-ANG2&VEGFA) (Ab175696) - ELISA Immobilized Recombinant Human VEGFA-His protein at 2.0 μg/mL can bind Vanucizumab (anti-ANG2&VEGFA) (Ab175696) with the EC₅₀ of 3.67 ng/mL.
Vanucizumab (anti-ANG2&VEGFA) (Ab175696) - SEC The purity of Vanucizumab (anti-ANG2&VEGFA) (Ab175696) is more than 95% verified by HPLC.
Certificates
C of A & Other Certificates
Find and download the COA for your product by matching the lot number on the packaging.
1.Spiess C, Zhai Q, Carter PJ. (2015) Alternative molecular formats and therapeutic applications for bispecific antibodies.. Mol Immunol, 67 (2 Pt A):(95-106). [PMID:25637431][10.1021/op500134e]
Solution Calculators
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.